Therapy Detail

Therapy Name DS-6051a
Synonym
Therapy Description

DS-6051a is the free base form of DS-6051b that inhibits ROS1 and NTRK1/2/3, which may lead to growth inhibition in tumor cells (PMID: 27477320).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
DS-6051a ROS1 Inhibitor 14 Trk Receptor Inhibitor (Pan) 23 DS-6051a is the free base form of DS-6051b that inhibits ROS1 and NTRK1/2/3, which may lead to growth inhibition in tumor cells (PMID: 27477320).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ETV6-NTRK3 melanoma sensitive DS-6051a Preclinical - Cell culture Actionable In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing ETV6-NTRK3 in culture (PMID: 27477320). 27477320
Clinical Trial Phase Therapies Title Recruitment Status